|Tuesday, November 2, 2010|
|17:30 - 19:30||Welcome Reception - Hosted by BioBay
Meet with speakers and other attendees at this informal reception
Octagon Restaurant, Dushu Lake Hotel
|Day 1 - Wednesday, November 3, 2010|
|08:00 - 09:00||Registration and Refreshments|
|09:00 - 09:30||Welcome Remarks||Greg Scott - President & Founder, ChinaBio® LLC|
|Yuwen Liu, MBA - Chairwoman & CEO, BioBay|
|09:30 - 10:00||Keynote: The State of China's Biotech Industry
China's healthcare industry is the world’s fastest growing at over 20%/year, but the drug, device, diagnostics and services sectors each have their own opportunities and challenges. Hear the latest data from ChinaBio's research team.
|Greg Scott - President & Founder, ChinaBio® LLC|
|Industry Sector Panels
Each sector of China's life science industry has its own characteristics: market size and growth, investor interest, government support, parterning opportunities, IP issues, etc. The four Industry Sector Panels - drugs, devices, diagnostics and services - will examine the state of each sector, how it is evolving, and the where the opportunities lie for entrepreneurs and investors alike. The panels will be made up of experts in that sector including VCs, entrepreneurs, executives from multinational companies, and industry consultants.
|10:00 - 11:00||Panel 1: Drugs - Novel vs Generics
Is China's drug development industry moving away from generics toward novel molecules, or are biosimilars becoming the "new" generics? What is the state of novel drug development in China, and what types of projects are attracting investment capital? Is the government stepping in to help fund pre-clinical compounds?
David Xu, PhD, MBA - Managing Partner, Mingly China Growth Fund
Leon Chen, PhD - Partner, Fidelity Asia Ventures
|Peng Chen, PhD, JD – Partner, Morrison & Foerster LLP|
|Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., Inc., USA|
|Peter (Peizhi) Luo, PhD - Founder & Chairman, Adagene Inc.|
|11:00 - 11:30||Networking Break and Refreshments|
|11:30 - 12:30||Panel 2: Device and Nano Technology - China's Next Frontier?
Medical devices and equipment are always attractive areas for investors, given the shorter development time, quicker exit and lower risk. But China has to-date been focused on lower-tech devices. Is this changing? And how will an increased focus on nanotechnology help propel technology development and investment in this area? Is IP protection a major concern for devices?
Karen Liu, PhD - VP, China Renaissance Capital Investment
|Jie Mi, PhD - Vice President, Gold Stone Investment Co., Ltd.|
|Joshua Ning, MBA - President & CEO, Suzhou DingMind Co., Ltd.|
|Bai Xu, PhD - President & CEO, Suzhou Natong Nanobiotechnology Co., Ltd.|
|Jason Zhao, MBA - Investment Director, SB China Venture Capital|
|12:30 - 14:00||Luncheon|
|14:00 - 17:00||Company Presentations||10 companies
|17:00 - 18:00||BioBay Tour / Shuttle Bus to Banquet|
|18:00 - 20:00||Gala Banquet
Suzhou Lao Beimen Restaurant
|Day 2 - Thursday, November 4, 2010|
|08:30 - 09:30||Registration and Refreshments|
|09:30 - 10:30||Panel 3: Diagnostics - What's the Prognosis?
When China announced its $124B funding for healthcare reforum, many thought this would stimulate technology development, especially in POC diagnostics. While this hasn't happened, many companies in the sector are still growing at 50% to 100% or more per year. Where are the opporutnities, and how could "theranostics" or "personalized medicine" impact this sector in China?
Francine Fang, MD, PhD - Senior Consultant, TusPark Ventures
Jian Han, MD, PhD – President & CSO, iCubate Inc.
|Marc A. Schueler, MD, PhD, MBA - Director Venturing, DSM|
|Victor Shi, PhD - President, Asia Pacific, QIAGEN|
|Stella Xu, PhD - Executive Director, Roche Global Pharma Partnering|
|10:30 - 11:00||Break and Refreshments|
|11:00 - 12:00||Panel 4: Services - Played Out or New Opportunities?
The world may not need another Wuxi Pharmatech or Chempartner, but are there still opportunities for speciliasts in this game? Could biologics CMOs be the next winning play in China? Do biology-based CROs offer enough scale to attract investment? Could China be facing over-capacity issues that are slowing investment?
Kewen Jin, PhD - General Manager, Charles River Greater China
Alex Fowkes, JD - Executive Director, Head of R&D Business Development, Pfizer Global Research & Development
|Timothy Wong, PhD - Marketing Development Manager, Drug Discovery, Pharma and CRO, Asia Pacific Invitrogen, by Life Technologies|
|Chun Wu, PhD - Founder & CEO, Abgent Biotechnology (Suzhou) Co.|
|Yanning Yi, MBA - Executive Director, The Balloch Group|
|12:00 - 13:30||Luncheon|
|13:30 - 16:00||Company Presentations||8 companies
|16:00 - 16:30||Raffle Drawings - Win valuable prizes
(Must be present to win)
|16:30 - 17:00||Award Ceremony / Closing Remarks|
|17:00 - 18:00||Closing Reception|